Double Your Impact on Millions of Lives
Double Your Impact on Millions of Lives
Now is the time to do more in the fight against Alzheimer’s and all other dementia. Give by July 20 and your gift can be matched, up to $35,000, to fund research that is helping protect brain health and provide care and support.
Donate NowDetailed Phase 2 Results From the CELIA Clinical Trial of Tau-Targeting Therapy Diranersen (BIIB080)
“These results are an encouraging step forward for people living with Alzheimer’s and their families,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead. “Today’s approved disease-modifying treatments target beta amyloid, and they are changing lives. But Alzheimer’s is a complex disease, and we must continue to pursue every promising research approach. For the first time in a Phase 2 trial, researchers demonstrated robust removal of tau from the brain — and that is the kind of signal that gives the field reason for optimism.”
“The Alzheimer’s Association envisions a future where there are multiple approved treatments that address the disease in multiple ways, and that may work together as powerful combination therapies, as combination therapies have transformed treatment of other complex diseases,” Carrillo said. “These results are a significant advancement toward that goal.”
The CELIA trial studied diranersen, an investigational therapy that targets tau — a protein that accumulates in the brain in Alzheimer’s disease — through a distinct mechanism from today’s approved amyloid-targeting treatments. The trial demonstrated consistent and reproducible reductions in tau across every dose tested in both the Phase 1 and Phase 2 trials. The trial also showed slowing of clinical decline across multiple measures, with the most robust response at the lowest dose studied. Biogen has announced it will advance to Phase 3. Diranersen is not approved by the FDA or other regulatory agencies and is not available outside of clinical trials.
The Alzheimer’s Association is deeply committed to advancing tau research, with more than $490 million in active and committed funding across more than 1,220 projects in 59 countries — more than 30% of which is related to tau. The Association also hosts the annual Tau Global Conference — next convening in Tokyo, Japan in June 2027 — bringing together leading scientists across academia, industry, government and philanthropy to drive transformative breakthroughs in tau research and treatment.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
About AAIC
AAIC is the world’s largest gathering of researchers from around the world focused on Alzheimer’s and other diseases that cause dementia. As a part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
- AAIC 2026: alz.org/aaic
- AAIC 2026 online pressroom: alz.org/aaic/pressroom.asp
- AAIC 2026 hashtag: #AAIC26